A Review of Vancomycin-Resistant Staphylococcus aureus Prevalence in Egypt and Saudi Arabia
Ahmed Elsayed Taha1,2★★ Corresponding author
- 1Department of Pathology, Microbiology and Immunology Unit, College of Medicine, Jouf University, Al-Jouf, SAUDI ARABIA.
- 2Department of Medical Microbiology and Immunology, Faculty of Medicine, Mansoura University, Mansoura, EGYPT.
CORRESPONDENCE
Ahmed Elsayed Taha
Department of Pathology, Microbiology and Immunology Unit, College of Medicine, Jouf University, Al-Jouf, SAUDI ARABIA.
Received: 22-07-2019; Revised: 16-09-2019; Accepted: 15-11-2019.
Volume 8, Issue 3 · pp. 83–88 · PUBLISHED 30 December 2019 · DOI: 10.5530/ajbls.2019.8.14
ABSTRACT
Staphylococcus aureusis considered an important and dangerous pathogen worldwide.Vancomycin was extensively used for treatment of the emerging methicillin-resistantStaphylococcusaureus(MRSA), but this led to the emergence of vancomycin-resistantStaphylococcus aureus(VRSA). Epidemiological and molecular data on VRSA are still scarce in both Egypt and SaudiArabia. We conducted the present study to review the emergence of VRSA in Egypt and SaudiArabia until December 2018. Among 220 VRSA isolates reported, only 10 of them were detectedin Saudi Arabia and the remaining 210 were detected in Egypt. Nearly, all the reported VRSAisolates were multidrug resistant. Many factors contribute to differences in the prevalence ofVRSA between Egypt and Saudi Arabia. Accurate diagnostic techniques, stringent infection control,rationale antibiotic use, environmental hygiene and improving the knowledge of the healthcareworkers about VRSA in Saudi Arabia are proved to be effective in limiting its spread.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Taha, A. E. (2019). A Review of Vancomycin-Resistant Staphylococcus aureus Prevalence in Egypt and Saudi Arabia. Asian Journal of Biological and Life sciences, 8(3), 83–88. https://doi.org/10.5530/ajbls.2019.8.14